{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:15:32Z","timestamp":1791123332171,"version":"4.1.0"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"abstract":"<jats:p>OBJECTIVE: Infantile hemangiomas (IHs) are the most-common soft-tissue tumors of infancy. We report the use of propranolol to control the growth phase of IHs.<\/jats:p>\n                  <jats:p>METHODS: Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4.2 months) after clinical and ultrasound evaluations. After electrocardiographic and echocardiographic evaluations, propranolol was administered with a starting dose of 2 to 3 mg\/kg per day, given in 2 or 3 divided doses. Blood pressure and heart rate were monitored during the first 6 hours of treatment. In the absence of side effects, treatment was continued at home and the child was reevaluated after 10 days of treatment and then every month. Ultrasound measurements were performed after 60 days of treatment.<\/jats:p>\n                  <jats:p>RESULTS: Immediate effects on color and growth were noted in all cases and were especially dramatic in cases of dyspnea, hemodynamic compromise, or palpebral occlusion. In ulcerated IHs, complete healing occurred in &amp;lt;2 months. Objective clinical and ultrasound evidence of longer-term regression was seen in 2 months. Systemic corticosteroid treatment could be stopped within a few weeks. Treatment was administered for a mean total duration of 6.1 months. Relapses were mild and responded to retreatment. Side effects were limited and mild. One patient discontinued treatment because of wheezing.<\/jats:p>\n                  <jats:p>CONCLUSION: Propranolol administered orally at 2 to 3 mg\/kg per day has a consistent, rapid, therapeutic effect, leading to considerable shortening of the natural course of IHs, with good clinical tolerance.<\/jats:p>","DOI":"10.1542\/peds.2008-3458","type":"journal-article","created":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T20:34:09Z","timestamp":1249936449000},"page":"e423-e431","source":"Crossref","is-referenced-by-count":439,"title":["Propranolol for Severe Infantile Hemangiomas: Follow-Up Report"],"prefix":"10.1542","volume":"124","author":[{"given":"Ve\u0301ronique","family":"Sans","sequence":"first","affiliation":[{"name":"National Reference Center for Rare Skin Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Dumas","family":"de la Roque","sequence":"additional","affiliation":[{"name":"Departments of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je\u0301ro\u0302me","family":"Berge","sequence":"additional","affiliation":[{"name":"Departments of Neuroradiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Grenier","sequence":"additional","affiliation":[{"name":"Radiology, Pellegrin Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boralevi","sequence":"additional","affiliation":[{"name":"National Reference Center for Rare Skin Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Mazereeuw-Hautier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Purpan Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lipsker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Strasbourg Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Dupuis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Fort de France Hospital, Fort de France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"National Reference Center for Rare Skin Diseases, Saint-Andre\u0301 Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vergnes","sequence":"additional","affiliation":[{"name":"Surgery, Children's Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Tai\u0308eb","sequence":"additional","affiliation":[{"name":"National Reference Center for Rare Skin Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Le\u0301aute\u0301-Labre\u0300ze","sequence":"additional","affiliation":[{"name":"National Reference Center for Rare Skin Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,9,1]]},"reference":[{"key":"2021120905044912000_R1","doi-asserted-by":"crossref","unstructured":"Frieden IJ, Haggstrom A, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions: proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol.\u20082005;22(5):383\u2013406","DOI":"10.1111\/j.1525-1470.2005.00102.x"},{"key":"2021120905044912000_R2","doi-asserted-by":"crossref","unstructured":"Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol.\u20082003;48(4):477\u2013493","DOI":"10.1067\/mjd.2003.200"},{"key":"2021120905044912000_R3","doi-asserted-by":"crossref","unstructured":"Margileth AM, Museles M. Cutaneous hemangiomas in children: diagnosis and conservative management. JAMA.\u20081965;194(5):523\u2013526","DOI":"10.1001\/jama.194.5.523"},{"key":"2021120905044912000_R4","doi-asserted-by":"crossref","unstructured":"Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol.\u20081997;14(3):173\u2013179","DOI":"10.1111\/j.1525-1470.1997.tb00232.x"},{"key":"2021120905044912000_R5","doi-asserted-by":"crossref","unstructured":"Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics.\u20081998;101(3):446\u2013452","DOI":"10.1542\/peds.101.3.446"},{"key":"2021120905044912000_R6","doi-asserted-by":"crossref","unstructured":"Bennett ML, Fleischer AB, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol.\u20082001;137(9):1208\u20131213","DOI":"10.1001\/archderm.137.9.1208"},{"key":"2021120905044912000_R7","doi-asserted-by":"crossref","unstructured":"Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics.\u20081990;85(4):491\u2013498","DOI":"10.1542\/peds.85.4.491"},{"key":"2021120905044912000_R8","doi-asserted-by":"crossref","unstructured":"Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg.\u20081986;17(4):229\u2013231","DOI":"10.3928\/1542-8877-19860401-07"},{"key":"2021120905044912000_R9","doi-asserted-by":"crossref","unstructured":"Ezekowitz RAB, Phil CBD, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med.\u20081992;326(22):1456\u20131463","DOI":"10.1056\/NEJM199205283262203"},{"key":"2021120905044912000_R10","doi-asserted-by":"crossref","unstructured":"Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function- and life-threatening infantile hemangioma[in French]. Arch Pediatr.\u20082004;11(2):99\u2013107","DOI":"10.1016\/j.arcped.2003.10.014"},{"key":"2021120905044912000_R11","doi-asserted-by":"crossref","unstructured":"Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with \u03b2-blocking therapy in children with long QT syndrome. Eur Heart J.\u20082004;25(16):1405\u20131411","DOI":"10.1016\/j.ehj.2004.06.016"},{"key":"2021120905044912000_R12","unstructured":"Fritz KI, Bhat AM. Effect of \u03b2-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. J Perinatol.\u20081998;18(1):38\u201344"},{"key":"2021120905044912000_R13","doi-asserted-by":"crossref","unstructured":"Kilian K. Hypertension in neonates causes and treatments. J Perinat Neonatal Nurs.\u20082003;17(1):65\u201374","DOI":"10.1097\/00005237-200301000-00006"},{"key":"2021120905044912000_R14","doi-asserted-by":"crossref","unstructured":"Le\u0301aute\u0301-Labre\u0300ze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Tai\u0308eb A. Propranolol for severe hemangiomas of infancy. N Engl J Med.\u20082008;358(24):2649\u20132651","DOI":"10.1056\/NEJMc0708819"},{"key":"2021120905044912000_R15","doi-asserted-by":"crossref","unstructured":"Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy. J Am Acad Dermatol.\u20081997;37(4):631\u2013637","DOI":"10.1016\/S0190-9622(97)70183-X"},{"key":"2021120905044912000_R16","unstructured":"Bakhach S, Grenier N, Berge J, et al. Color Doppler sonography of superficial capillary hemangiomas [in French][in French]. J Radiol.\u20082001;82(11):1613\u20131619"},{"key":"2021120905044912000_R17","unstructured":"Maleville J, Tai\u0308eb A, Roubaud E, Sarrat P, Fontan I, Guillet G. Immature cutaneous hemangiomas: epidemiologic study of 351 cases [in French]. Ann Dermatol Venereol.\u20081985;112(8):603\u2013608"},{"key":"2021120905044912000_R18","doi-asserted-by":"crossref","unstructured":"Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behaviour of endothelial cells from hemangiomas. J Clin Invest.\u20082001;107(6):745\u2013752","DOI":"10.1172\/JCI11432"},{"key":"2021120905044912000_R19","doi-asserted-by":"crossref","unstructured":"Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest.\u20082008;118(7):2592\u20132599","DOI":"10.1172\/JCI33493"},{"key":"2021120905044912000_R20","doi-asserted-by":"crossref","unstructured":"Bielenberg DR, Bucana CD, Sanchez R, Mulliken JB, Folkman J, Fidler IJ. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, INF-\u03b2. Int J Oncol.\u20081999;14(3):401\u2013408","DOI":"10.3892\/ijo.14.3.401"},{"key":"2021120905044912000_R21","doi-asserted-by":"crossref","unstructured":"Mancini AJ, Smoller BR. Proliferation and apoptosis within juvenile capillary hemangiomas. Am J Dermatopathol.\u20081996;18(5):505\u2013514","DOI":"10.1097\/00000372-199610000-00009"},{"key":"2021120905044912000_R22","doi-asserted-by":"crossref","unstructured":"Razon MJ, Kraling BM, Mulliken JB, Bischoff J. Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation.\u20081998;5(2\u20133):189\u2013195","DOI":"10.1111\/j.1549-8719.1998.tb00068.x"},{"key":"2021120905044912000_R23","doi-asserted-by":"crossref","unstructured":"Iaccarino G, Ciccarelli M, Sorriento D, et al. Ischemic neoangiogenesis enhanced by \u03b22-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res.\u20082005;97(11):1182\u20131189","DOI":"10.1161\/01.RES.0000191541.06788.bb"},{"key":"2021120905044912000_R24","doi-asserted-by":"crossref","unstructured":"D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem.\u20081997;67(3):353\u2013366","DOI":"10.1002\/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.0.CO;2-V"},{"key":"2021120905044912000_R25","doi-asserted-by":"crossref","unstructured":"Verhoeckx KC, Doornbos RP, Witkamp RF, van der Greef J, Rodenburg RJ. \u03b2-Adrenergic receptor agonists induce the release of granulocyte chemotactic protein-2, oncostatin M, and vascular endothelial growth factor from macrophages. Int Immunopharmacol.\u20082006;6(1):1\u20137","DOI":"10.1016\/j.intimp.2005.05.013"},{"key":"2021120905044912000_R26","doi-asserted-by":"crossref","unstructured":"Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem\/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol.\u20082007;27(12):2664\u20132670","DOI":"10.1161\/ATVBAHA.107.150284"},{"key":"2021120905044912000_R27","doi-asserted-by":"crossref","unstructured":"Giatromanolaki A, Arvanitidou V, Hatzimichael A, Simopoulos C, Sivridis E. The HIF-2\u03b1\/VEGF pathway activation in cutaneous capillary hemangiomas. Pathology.\u20082005;37(2):149\u2013151","DOI":"10.1080\/00313020400025011"},{"key":"2021120905044912000_R28","doi-asserted-by":"crossref","unstructured":"Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1\u03b1 and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci.\u20082005;12(2):409\u2013420","DOI":"10.1007\/s11373-005-3008-x"},{"key":"2021120905044912000_R29","doi-asserted-by":"crossref","unstructured":"Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim.\u20082002;38(5):298\u2013304","DOI":"10.1290\/1071-2690(2002)038<0298:BBIAIC>2.0.CO;2"},{"key":"2021120905044912000_R30","doi-asserted-by":"crossref","unstructured":"Love JN, Sikka N. Are 1\u20132 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med.\u20082004;26(3):309\u2013314","DOI":"10.1016\/j.jemermed.2003.11.015"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/3\/e423\/1006491\/zpe0090900e423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/3\/e423\/1006491\/zpe0090900e423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:51:15Z","timestamp":1685076675000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/124\/3\/e423\/71813\/Propranolol-for-Severe-Infantile-Hemangiomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,9,1]]},"published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-3458","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1164653.626452","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1164653.627306","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]}}}